Evidence map›Paper›PMID 33945054›Full record

ArticleBiotechnology letters2021

Mutant firefly luciferase enzymes resistant to the inhibition by sodium chloride.

Satoshi Yawata, Kenichi Noda, Ai Shimomura, Akio Kuroda

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Satoshi YawataMedical Related Devices Department, DKK-TOA Corporation, Sayama, Saitama, 350-1388, Japan. s-yawata@toadkk.co.jp.ORCID http://orcid.org/0000-0002-2572-4107
Kenichi NodaResearch and Development Planning Department, DKK-TOA Corporation, Sayama, Saitama, 350-1388, Japan.
Ai ShimomuraResearch and Development Planning Department, DKK-TOA Corporation, Sayama, Saitama, 350-1388, Japan.
Akio KurodaUnit of Molecular Biotechnology, Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Hiroshima, 739-8530, Japan. akuroda@hiroshima-u.ac.jp.
Hiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesFirefly luciferase, one of the most extensively studied enzymes, has numerous applications. However, luciferase activity is inhibited by sodium chloride. This study was aimed at obtaining mutant luciferase enzymes resistant to the sodium chloride inhibition.

resultsWe first obtained two mutant luciferase enzymes whose inhibition were alleviated and determined the mutations to be Val288Ile and Glu488Val. Under medical dialysis condition (140 mM sodium chloride), the wild type was inhibited to 44% of its original activity level. In contrast, the single mutants, Val288Ile and Glu488Val, retained 67% and 79% of their original activity, respectively. Next, we introduced Val288Ile and Glu488Val mutations into wild-type luciferase to create a double mutant using site-directed mutagenesis. Notably, the double mutant retained its activity more than 95% of that in the absence of sodium chloride.

conclusionsThe mutant luciferase, named luciferase CR, was found to retain its activity in various concentrations of sodium chloride. The luciferase CR may be extensively useful in any bioassay which includes firefly luciferase and is employed in the presence of sodium chloride.

Indexed as

AnimalsEscherichia coliFirefliesLuciferases, FireflyLuminescent MeasurementsMutagenesis, Site-DirectedMutant ProteinsSodium ChlorideLuciferases, FireflyMutant ProteinsSodium ChlorideAlleviationLuciferaseMutationSalt inhibition

Identifiers

PMID33945054
OpenAlexW3134849137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.